Mod GRF 1-29 vs Survodutide
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Mod GRF 1-29
Mod GRF 1-29 (Modified GRF 1-29, also called CJC-1295 without DAC or Tetrasubstituted GRF 1-29) is a modified growth hormone-releasing hormone analog with improved stability over natural GHRH.
Full details →Survodutide
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is being developed primarily for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and obesity. Survodutide's glucagon receptor activation promotes hepatic fat mobilization, making it uniquely suited for liver-related metabolic conditions.
Full details →Side-by-Side Comparison
| Aspect | Mod GRF 1-29 | Survodutide |
|---|---|---|
| Mechanism | Binds to GHRH receptors in the pituitary gland to stimulate growth hormone release. Four amino acid substitutions improve resistance to enzymatic degradation while maintaining biological activity. | Survodutide activates both GLP-1 and glucagon receptors. The GLP-1 component provides appetite suppression, glucose-dependent insulin secretion, and delayed gastric emptying. The glucagon component drives hepatic fat oxidation, increases energy expenditure, and promotes lipolysis. This dual mechanism is particularly effective for MASH, where hepatic fat accumulation is the core pathology. Unlike tirzepatide (which targets GIP/GLP-1), survodutide targets glucagon/GLP-1 — a different receptor combination optimized for liver and metabolic outcomes. |
| Typical Dosage | Typical dosing: 100-300mcg administered 2-3 times daily, usually combined with a GHRP like Ipamorelin for synergistic effects. | Phase 2 MASH trial: escalated to 2.4 mg, 4.8 mg, or 6.0 mg weekly. Phase 2b obesity trial: up to 6.0 mg weekly. Dose escalation over 16-20 weeks to manage GI tolerability. Final approved dosing not yet established — Phase 3 trials ongoing. |
| Administration | Subcutaneous injection. Best administered on empty stomach. Short half-life (~30 minutes) necessitates multiple daily doses, unlike DAC version. | Subcutaneous injection, once weekly. Phase 3 trials use pre-filled pens. Not yet commercially available. Phase 3 results expected 2026-2027. |
| Side Effects | Flushing, headache, dizziness, and injection site reactions. Generally well-tolerated. May cause water retention. | Phase 2 data: nausea, vomiting, diarrhea (dose-dependent, generally transient). Reduced appetite. Transient increases in heart rate. The GI side effect profile appears similar to other GLP-1 agonists. |
| Best For |
Key Differences
Unique to Mod GRF 1-29:
Unique to Survodutide:
Detailed Analysis
Commonalities
Mod GRF 1-29 and Survodutide are used for different purposes and have limited overlap in their applications.
Which Should You Choose?
Choose Mod GRF 1-29 for Muscle Growth, Fat Loss, Recovery & Healing, Sleep Quality. Choose Survodutide for Weight Loss, Liver Health.
Ready to Learn More?
Looking for trusted sources?